Family planning improves child survival and reduces maternal deaths. But the uptake of family planning in Africa is only 33%, nearly half the world average of 64%. The contraceptive prevalence rate in African countries is considerably low despite an increase in demand.
Niger has one of the highest fertility rates globally. Women of reproductive age have, on average, eight children. Niger has a maternal mortality ratio of 553 per 100,000 live births and an under-five mortality rate of 104 per 1000 live births. Mauritius has the lowest child mortality rate in Africa at 12 per 1,000 live births.
In Niger, 13% of children under five years die from various illnesses. The country is one of the top five that account for half of these deaths in the world.
The low provision of family planning across sub-Saharan Africa is cited as one of the main reasons for the region’s high maternal mortality rates. A lack of family planning leads to unintended pregnancies and often means that women deliver their babies with very low skilled assistance. This, in turn, pushes up the rate of newborn deaths.
Access to family planning services, particularly in developing countries, should be improved.
But Trump wants to go even further than his GOP predecessors by slashing spending on global health efforts funded through the United States Agency for International Development (USAID). Deeper family planning retrenchment would, however, put millions of lives at risk.
South Africa has extremely high maternal mortality levels. This is true when compared with developed countries as well as other developing countries.
According to the World Health Organisation, for every 100,000 live births in the country in 2015, 138 women died due to pregnancy and childbirth complications. In Sweden, fewer than five women die for every 100,000 live births. In Brazil, the estimate is 44 women for every 100,000 live births.
Launched four years ago, the two clinical trials, known as ASPIRE and The Ring Study, set out to determine how safe and effective the ring was in prevention of HIV infection in women. The ring, which is used for a month at a time, contains an antiretroviral drug called dapivirine that acts by blocking HIV from multiplying.
The studies enrolled close to 4500 women aged 18 to 45 in South Africa, Uganda, Malawi and Zimbabwe. Each study found that the ring helps reduce the risk of HIV infection in women. In ASPIRE, the ring reduced the risk of HIV infection by 27% overall. In The Ring Study, infections were reduced by 31% overall.